secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2022-05-24T23:59:59+00:00
Accession:  0001125345-22-000070
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics appoints William Heiden as Board Chair, replacing Paulo Costa
-------------------------------------------------------------------------

- William Heiden appointed as non-executive Chair of the Board and director, effective May 22, 2022.
- Heiden replaces Paulo Costa, whose term expired at 2022 Annual Meeting on May 19.
- Heiden also appointed to Audit Committee; granted option to purchase 36,000 shares at $3.96, vesting monthly over 36 months.
- Board now comprises 8 directors, 7 of whom are independent.
- Heiden brings 35 years biopharma experience, most recently CEO of AMAG Pharmaceuticals (acquired 2020 for $650M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000070/0001125345-22-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534522000070/mgnx-20220522.htm
  HTML page:      https://secwatch.observer/filing/0001125345-22-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer